Why Psyence Biomedical Ltd.’s (PBM) Stock Is Up 9.01%
As of Friday, July 25, Psyence Biomedical Ltd.’s PBM share price has surged by 9.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Commentary & Analysis
Why Psyence Biomedical Ltd.’s (PBM) Stock Is Up 14.21%
As of Friday, July 25, Psyence Biomedical Ltd.’s PBM share price has surged by 14.21%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | PBM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $21.2 | $257.9 | 10% |
|
| Shares Out (Mil) | 0.9 | 54.3 | 4% |
|
| Institutional Ownership | 87.4% | 92.9% | 55% |
|
| Float (Mil) | 2.6 | 41.4 | 7% |
|
| Beta | 1.73 | 0.95 | 87% |
|
| Avg Daily Volume (000s) | 136 | 674 | 38% |
|
| Price Change (52-week) |
(75.4%) | 51.5% | 9% |
|
| Growth | PBM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PBM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($43) | 32% |
|
| EPS (TTM) | ($12.560) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($32) | 22% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $9 | $174 | 7% |
|
| Valuation | PBM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.75 | 2.51 | 14% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PBM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (55.8%) | (47.7%) | 10% |
|
| ROE | (58.6%) | (54.9%) | 14% |
|
| Liabilities to Assets | 3.5% | 29.1% | 1% |
|
| F-Score | 1 | 3 | na |
|
Psyence Biomedical Ltd. did not pass any screens on 9/25/2026.
